Published in Clin Cancer Res on August 21, 2013
The Globalization of Cooperative Groups. Semin Oncol (2015) 0.82
The tumor-suppressive microRNA-135b targets c-myc in osteoscarcoma. PLoS One (2014) 0.80
The network of pluripotency, epithelial-mesenchymal transition, and prognosis of breast cancer. Breast Cancer (Dove Med Press) (2015) 0.80
Canine epidermal neural crest stem cells: characterization and potential as therapy candidate for a large animal model of spinal cord injury. Stem Cells Transl Med (2014) 0.78
Identification a novel tumor-suppressive hsa-miR-599 regulates cells proliferation, migration and invasion by targeting oncogenic MYC in hepatocellular carcinoma. Am J Transl Res (2016) 0.78
Towards tumor immunodiagnostics. Ann Transl Med (2016) 0.75
Human Cancer Cells Signal Their Competitive Fitness Through MYC Activity. Sci Rep (2017) 0.75
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol (2005) 7.54
Reflecting on 25 years with MYC. Nat Rev Cancer (2008) 7.44
Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol (2010) 5.25
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol (2011) 4.81
Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res (1999) 4.74
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol (2005) 4.03
Myc pathways provoking cell suicide and cancer. Oncogene (2003) 3.49
The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene (1999) 3.17
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol (2011) 3.02
c-Myc in breast cancer. Endocr Relat Cancer (2000) 2.32
Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol (2006) 2.17
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol (2013) 2.15
Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene (2000) 2.01
Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker? Cancer (2003) 1.88
MYC and Breast Cancer. Genes Cancer (2010) 1.66
Contributions of Myc to tumorigenesis. Biochim Biophys Acta (2002) 1.63
HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc (2002) 1.59
Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg (1995) 1.24
Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Int J Mol Med (2002) 1.22
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol (2011) 1.21
Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer (2004) 1.19
Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin Cancer Res (2006) 1.16
Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res (1988) 1.16
c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res (1992) 1.13
Enigmatic MYC Conducts an Unfolding Systems Biology Symphony. Genes Cancer (2010) 1.11
Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose. Cancer Res (2010) 1.08
c-myc oncogene product expression and prognosis in operable breast cancer. Br J Cancer (1989) 1.06
Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. Curr Cancer Drug Targets (2009) 0.98
An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas. J Pathol (1989) 0.98
Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis. Oncogene (2000) 0.97
Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors? J Clin Oncol (2006) 0.96
Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters. Exp Mol Pathol (2005) 0.95
Steroid hormone receptor immunohistochemistry and amplification of c-myc protooncogene. Relationship to disease-free survival in breast cancer. Cancer (1993) 0.94
Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival. Anticancer Res (1995) 0.89
MYC genes with differential responses to tapping, mechanical wounding, ethrel and methyl jasmonate in laticifers of rubber tree (Hevea brasiliensis Muell. Arg.). J Plant Physiol (2011) 0.86
Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas. Anticancer Res (1992) 0.82
ras, c-myc and c-erbB-2 oncoproteins in human breast cancer. Anticancer Res (1990) 0.81
Evaluation of c-myc proto-oncogene in primary human breast carcinomas. Anticancer Res (1992) 0.81
C-myc gene chromatin of estrogen receptor positive and negative breast cancer cells. Mol Cell Endocrinol (1993) 0.80
Trastuzumab. Cancer Treat Res (2009) 0.79
Immunohistochemical detection of TGF-alpha, EGF-R, c-erbB-2, c-H-ras, c-myc, estrogen and progesterone in benign and malignant human breast lesions: a concomitant expression. In Vivo (1994) 0.79
Preliminary study on oncogene product immunohistochemistry (c-erbB-2, c-myc, ras p21, EGFR) in breast pathology. Int J Biol Markers (1992) 0.77
Estradiol receptors in combination with neu or myc oncogene amplifications might define new subtypes of breast cancer. Clin Chim Acta (1994) 0.77
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Estrogen carcinogenesis in breast cancer. N Engl J Med (2006) 8.17
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet (2006) 7.16
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat Genet (2004) 6.85
Benign breast disease and the risk of breast cancer. N Engl J Med (2005) 6.84
Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet (2010) 6.84
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med (2008) 6.54
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med (2010) 5.17
Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg (2011) 5.14
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet (2009) 5.13
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol (2008) 5.10
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med (2015) 5.03
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol (2011) 4.81
American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol (2006) 4.61
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol (2006) 4.55
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med (2015) 4.53
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol (2008) 4.42